Table 1 Patient characteristics.
All (n = 51) | PTX + RAM (n = 41) | Nab-PTX + RAM (n = 10) | ||
|---|---|---|---|---|
Age | Median (range) | 70 (41–83) | 69 (41–81) | 74.5 (48–82) |
Sex | Male | 30 (59%) | 24 (59%) | 6 (60%) |
PS | 0 | 11 (22%) | 9 (22%) | 2 (20%) |
1 | 34 (67%) | 27 (66%) | 7 (70%) | |
2 or 3 | 6 (12%) | 5 (12%) | 1 (10%) | |
Location | Esophago-gastric junction | 5 (10%) | 5 (12%) | 0 |
Gastric | 46 (90%) | 36 (88%) | 10 (100%) | |
Gastrectomy | Yes | 14 (27%) | 11 (27%) | 3 (30%) |
Pathology | Diffuse | 32 (63%) | 26 (63%) | 6 (60%) |
Number of metastatic organs | ≥ 2 | 31 (61%) | 24 (59%) | 7 (70%) |
Liver metastasis | Yes | 14 (27%) | 12 (29%) | 2 (20%) |
Peritoneum dissemination | Yes | 30 (59%) | 24 (59%) | 6 (60%) |
Ascites | Yes | 25 (49%) | 20 (50%) | 5 (50%) |
Regimen | Paclitaxel | 41 (80%) | 41 (100%) | 0 |
Nab-paclitaxel | 10 (20%) | 0 | 10 (100%) | |
PD-L1 | Unknown | 15 (29%) | 13 (32%) | 2 (20%) |
< 1 | 7 (14%) | 5 (12%) | 2 (20%) | |
≥ 1 | 29 (57%) | 23 (56%) | 6 (60%) | |
≥ 5 | 18 (35%) | 14 (34%) | 4 (40%) | |
MSI | MSI-high | 2 (4%) | 2 (5%) | 0 |
MSS | 25 (50%) | 18 (44%) | 7 (70%) | |
Unknown | 24 (47%) | 21 (51%) | 3 (30%) | |
1st-line regimen | SOX + nivolumab | 38 (75%) | 29 (71%) | 9 (90%) |
FOLFOX + nivolumab | 9 (18%) | 8 (20%) | 1 (10%) | |
CapeOX + nivolumab | 4 (8%) | 4 (10%) | 0 | |
Efficacy of 1st line therapy | CR/PR | 23 (45%) | 19 (46%) | 4 (40%) |
PFS of 1st line | Median (range) | 7.1 months (1.4–40.1) | 6.6 (1.4–40.1) | 9.6 (2.1–28.4) |
Reason of 1st line therapy discontinuation | Disease progression | 49 (96%) | 39 (95%) | 10 (100%) |
Adverse events | 2 (4%) | 2 (5%) | 0 |
